April 21, 2011 - Philips Healthcare and Corindus Inc. today announced an alliance agreement to add Corindus’ robotic-assisted cath lab navigation system for percutaneous coronary interventions (PCI) to Philips’ interventional cardiology solutions.
The Corindus system is currently in a U.S. Food and Drug Administration pivotal trial. The system allows the operator to sit in a lead-shielded booth in the cath lab to perform procedures away from the table and outside of the radiation field. The system allows operators to work while sitting down, without lead aprons and with more precision than allowed with hand manipulation.
As part of the alliance agreement, Philips has acquired a minority stake in Corindus. The financial terms of the agreement were not disclosed.
The trend towards image-guided minimally invasive interventions continues to grow, requiring image guidance and catheter controls that enable physicians to optimally perform their procedures. Procedure innovation, driven by the combination of advanced imaging tools, new interventional devices and improved delivery controls, is aimed at simplifying the procedures and facilitating instantly informed decision making, while further reducing discomfort to the patient and the physician.
“Personalized and less-invasive treatments are the way forward in patient care,” said Steve Rusckowski, CEO for Philips Healthcare. “As part of our strategy, Philips is committed to delivering integrated interventional solutions for image-guided minimally invasive procedures by working closely with hospitals and industrial partners in different application spaces. Corindus’ advanced interventional tool designed for percutaneous coronary interventions opens up further possibilities of reducing the strain on cardiologists, helping to advance patient care.”
“Everything in the catheterization lab, from X-ray imaging to coronary stents to contrast media, has advanced significantly over the past thirty years. However, the procedural process itself has remained largely unchanged,” said David Handler, president and CEO of Corindus. “We are excited by the possibility of putting the power of remote precision robotic control into the hands of interventional cardiologists. Partnering with Philips will strengthen our ability to develop integrated technologies, with the ultimate objective of advancing interventional cardiology.”
Corindus’ CorPath 200 System has been designed to provide precise, robotic-assisted placement of coronary guide wires and stent/balloon catheters in PCI procedures. In March, Corindus announced that the first patients had been enrolled in its FDA approved CorPath PRECISE trial, which is expected to enlist 175 patients at leading medical centers across the United States. The results of this study will be the basis for a pre-market clearance 510(k) application to the FDA.
The CorPath 200 System is an investigational device and limited by federal law to investigational use only.
For more information: www.philips.com, www.corindus.com
March 18, 2024 
